Nestec S.a.

Fred Princen

Sharat Singh

Fabiyola Selvaraj

Stefan Westin

Steven Lockton

Nicholas Chi-Kwan Ling

Lisa Croner

Derren Barken

Thomas Stockfisch

Shui-Long Wang

Leonard Eggleston

Frederick A Fletcher

Lisa J Croner

The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Pathway specific markers for diagnosing irritable bowel syndrome

The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.

Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS

The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and sensitive immunoassays The present invention also provides stable derivatives of various metabolites and short chain fatty acids. The derivative can be conjugated to a biomolecule such as a carrier protein and combined with an adjuvant to stimulate an immune response. The derivatives can also be conjugated to other biomolecules.

Pathway specific assays for predicting irritable bowel syndrome diagnosis

The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery.

Method for determining the risk of crohn's disease-related complications

The present invention provides compositions, methods, and kits for discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides compositions, methods, and kits for determining the presence and/or level (e.g., quantitating) of rare (e.g., mutant) allelic variants, such as single nucleotide polymorphisms (SNPs) or nucleotide insertions or deletions, in samples comprising abundant (e.g., wild-type) allelic variants with high sensitivity and/or specificity. As such, in certain embodiments, the present invention provides a highly selective method for the detection of somatic mutations, e.g., in samples containing abundant levels of a wild-type allele compared to very low levels of a mutant allele.

Compositions and methods for detecting allelic variants

The present invention provides methods and systems to predict and diagnose inflammatory bowel disease (IBD) and subtypes such as ulcerative colitis (UC) and Crohn's disease (CD) by detecting the presence, absence, level, and/or genotype of one or more sero-genetic-inflammation markers. Advantageously, with the present invention, it is possible to provide a diagnosis of IBD versus non-IBD, to rule out IBD that is inconclusive for CD and UC, and to differentiate between CD and UC with increased accuracy.

Growing community of inventors

La Jolla, CA, United States of America

Fred Princen